Elkfork Partners’s Haemonetics HAE Stock Holding History

Elkfork Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$999K	Buy	7,920 +264	+3%	+$33.5K	0.02%	386
2019 Q2	$921K	Hold	7,656	–	–	0.02%	411
2019 Q1	$670K	Buy	7,656 +264	+4%	+$24K	0.02%	484
2018 Q4	$740K	Hold	7,392	–	–	0.02%	415
2018 Q3	$847K	Buy	7,392 +1,628	+28%	+$169K	0.02%	425
2018 Q2	$517K	Hold	5,764	–	–	0.01%	523
2018 Q1	$422K	Hold	5,764	–	–	0.01%	576
2017 Q4	$335K	Buy	5,764 +990	+21%	+$52.1K	0.01%	652
2017 Q3	$214K	Buy	4,774 +484	+11%	+$20.1K	0.01%	720
2017 Q2	$169K	Buy	4,290 +1,980	+86%	+$81.3K	0.01%	741
2017 Q1	$94K	Hold	2,310	–	–	﹤0.01%	767
2016 Q4	$93K	Buy	+2,310	New	+$87.1K	﹤0.01%	758

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Elkfork Partners's HAE Position: Q3 2019 in Review

Elkfork Partners increased its Haemonetics (HAE) stake by 3.4% in Q3 2019, buying an estimated $33.5K and bringing the position to 7,920 shares worth $999K. The position accounts for 0.02% of the portfolio, ranked #386.

Elkfork Partners first reported a position in HAE in Q4 2016 and has held it in 12 quarters since. 275 funds tracked by Wall St. Rank hold HAE as of Q3 2019.

Elkfork Partners held 7,920 shares of Haemonetics worth $999K as of Q3 2019.
Elkfork Partners bought 264 Haemonetics shares in Q3 2019, an estimated $33.5K.
Haemonetics made up 0.02% of Elkfork Partners's portfolio in Q3 2019, its #386 holding.
Elkfork Partners first reported a position in Haemonetics in Q4 2016 and has held it in 12 quarters since.
275 funds tracked by Wall St. Rank held Haemonetics as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.